scholarly journals Effect of Continuous Melatonin Administration on the Diurnal Rhythms of the Peripheral Blood Leukocyte Counts in Chicks

1997 ◽  
Vol 68 (1) ◽  
pp. 38-40
Author(s):  
Yasuhiro KONDO ◽  
Yuri OOYA ◽  
Asaki ABE ◽  
Koji SATO
Keyword(s):  
Peripheral Blood ◽  
Peripheral Blood Leukocyte ◽  
Diurnal Rhythms ◽  
Melatonin Administration ◽  
Leukocyte Counts ◽  
Blood Leukocyte

scholarly journals Subnormal Peripheral Blood Leukocyte Counts Are Related to the Lowest Prevalence and Incidence of Metabolic Syndrome: Tianjin Chronic Low-Grade Systemic Inflammation and Health Cohort Study

2014 ◽  
Vol 2014 ◽  
pp. 1-12 ◽  
Author(s):  
Shaomei Sun ◽  
Hongmei Wu ◽  
Qing Zhang ◽  
Chongjin Wang ◽  
Yinting Guo ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Cohort Study ◽  
Peripheral Blood ◽  
Peripheral Blood Leukocyte ◽  
Cox Proportional Hazards ◽  
Low Grade ◽  
Cross Sectional ◽  
Inflammatory Status ◽  
Leukocyte Counts ◽  
Blood Leukocyte

Few studies have assessed the relationship between a subnormal inflammatory status and metabolic syndrome (MS). We therefore designed a cross-sectional and 5-year cohort study to evaluate how a subnormal peripheral blood leukocyte count is related to MS. Participants were recruited from Tianjin Medical University General Hospital-Health Management Centre. Both a baseline cross-sectional (n=46,179) and a prospective assessment (n=13,061) were performed. Participants without a history of MS were followed up for 5 years. Leukocyte counts and MS components were assessed at baseline and yearly during the follow-up. Adjusted logistic and Cox proportional hazards regression models were used to assess relationships between the categories of leukocyte counts and MS. The subnormal leukocyte counts group (1,100–3,900 cells/mm3) had the lowest prevalence and incidence of MS. The odds ratio and hazard ratio (95% confidence interval) of the highest leukocyte counts were 1.98 (1.57–2.49) and 1.50 (1.22–1.84) (bothPfor trend <0.0001), respectively, when compared to the subnormal leukocyte counts group after adjusting for potential confounders. This study has shown that subnormal leukocyte counts are independently related to the lowest prevalence and incidence of MS. The findings suggest that it is necessary to restudy and discuss the clinical or preventive value of subnormal leukocyte counts.

COMPARATIVE EFFECTS OF NITROGEN MUSTARD (HN2), CHLORAMBUCIL (CB 1348), AND BUSULPHAN (MYLERAN) ON THE PERIPHERAL BLOOD AND THE FERROKINETIC PATTERNS IN DOGS

1962 ◽  
Vol 40 (5) ◽  
pp. 667-677 ◽  
Author(s):  
L. G. Israels ◽  
C. Sinclair ◽  
J. Graf ◽  
A. Zipursky
Keyword(s):  
Peripheral Blood ◽  
Alkylating Agents ◽  
Peripheral Blood Leukocyte ◽  
Red Cell ◽  
Inhibitory Effects ◽  
Cell Production ◽  
Plasma Iron ◽  
Leukocyte Counts ◽  
Blood Leukocyte ◽  
Phenylbutyric Acid

Three alkylating agents, HN2 (methyl-bis(betachlorethyl)amine), chlorambucil (p-(di-2-chlorethylamino)-phenylbutyric acid), and busulphan (1,4-dimethanesulphonoxybutane) were studied with regard to their effects on leukocyte and red cell production in dogs. This was assessed by estimation of the peripheral blood leukocyte and reticulocyte changes as well as alterations in the plasma iron, Fe59 disappearance rate, plasma iron turnover, and red cell incorporation of radioactive iron. The two chlorethylamines had a similar effect on both leukocyte and red cell production. The effect on peripheral leukocyte counts was evident in 24 hours and the reticulocyte response indicated maximum interference with erythropoiesis on the third to seventh day following the drug. The effect of busulphan on both granulocytes and lymphocytes was slower to appear and slowly progressive. A difference in ferrokinetic pattern between the chlorethylamines and busulphan was also noted. The dissimilarity in ferrokinetic patterns may indicate a difference not only in mechanism of these agents on proliferating normoblasts but also in the inhibitory effects on the acceptance of iron by the red cell precursors and other body iron pools.

The Relation Between Peripheral Blood Leukocyte Counts and Respiratory Symptoms, Atopy, Lung Function, and Airway Responsiveness in Adults

CHEST Journal ◽  
2001 ◽  
Vol 119 (1) ◽  
pp. 105-114 ◽  
Author(s):  
Sarah A. Lewis ◽  
Ian D. Pavord ◽  
John R. Stringer ◽  
Alan J. Knox ◽  
Scott T. Weiss ◽  
...  
Keyword(s):  
Lung Function ◽  
Peripheral Blood ◽  
Respiratory Symptoms ◽  
Peripheral Blood Leukocyte ◽  
Airway Responsiveness ◽  
Leukocyte Counts ◽  
Blood Leukocyte

Involvement of nitric oxide in the regulation of peripheral blood leukocyte counts

1995 ◽  
Vol 58 (4) ◽  
pp. 391-394 ◽  
Author(s):  
Jorge R. Geffner ◽  
Analía S. Trevani ◽  
Isabel de D'Elia ◽  
Miriam Diament ◽  
Danka Klein ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Peripheral Blood ◽  
Peripheral Blood Leukocyte ◽  
Leukocyte Counts ◽  
Blood Leukocyte

scholarly journals Lymphopenia and DMTs for relapsing forms of MS

2019 ◽  
Vol 9 (1) ◽  
pp. 53-63 ◽  
Author(s):  
Edward J. Fox ◽  
Guy J. Buckle ◽  
Barry Singer ◽  
Vibhuti Singh ◽  
Aaron Boster
Keyword(s):  
Peripheral Blood ◽  
Immune Surveillance ◽  
Drug Efficacy ◽  
Peripheral Blood Leukocyte ◽  
Patient Characteristics ◽  
Blood Leukocytes ◽  
Leukocyte Counts ◽  
Absolute Lymphocyte Counts ◽  
Blood Leukocyte

Purpose of reviewTo provide neurologists with an update on the proposed mechanisms of action (MOAs) of disease-modifying therapies (DMTs) for the treatment of relapsing MS, and their effect on peripheral blood leukocytes, in order to inform treatment decisions.Recent findingsDMTs have vastly differing MOAs, including effects on peripheral blood leukocyte counts, particularly lymphocytes. The clinical implications of changes in lymphocyte counts need to be understood in the context of the underlying MOAs of each respective DMT, with treatment tailored to individual patient needs.SummaryDMTs can alter lymphocyte counts, subsets, activation, and distribution, and thus can influence immune surveillance. Serial monitoring of total leukocytes and absolute lymphocyte counts (ALCs) is advisable in patients receiving DMTs. ALCs should be interpreted regarding expected immunologic changes and individual patient characteristics. Any decision to switch DMTs should consider these factors, along with drug efficacy, safety, and effect on quality of life.

Sign in / Sign up

Export Citation Format

Share Document